Barbaloin Protects Pentylenetetrazol-Induced Cognitive Deficits in Rodents via Modulation of Neurotransmitters and Inhibition of Oxidative-Free-Radicals-Led Inflammation.
Ahmad Essam AltyarMuhammad AfzalNehmat GhabouraKhalid Saad AlharbiSattam Khulaif AleneziNadeem SayyedImran KazmiPublished in: Pharmaceuticals (Basel, Switzerland) (2024)
The ongoing study has gathered evidence indicating that the injection of barbaloin has resulted in significant improvements in cognitive performance in rats. This is achieved by inhibiting oxidative stress, enhancing the activity of natural antioxidant enzymes, reducing cytokine levels, and increasing the levels of neurotransmitters in the brain. These results were detected in comparison to a PTZ control and can be attributed to the potent anti-inflammatory and antioxidant capabilities of barbaloin, which could be linked to its neuroprotective properties. Barbaloin may potentially increase cognitive decline and boost neuronal survival by altering the expression of
Keyphrases
- oxidative stress
- anti inflammatory
- cognitive decline
- diabetic rats
- mild cognitive impairment
- cerebral ischemia
- poor prognosis
- dna damage
- ischemia reperfusion injury
- induced apoptosis
- signaling pathway
- resting state
- high glucose
- white matter
- subarachnoid hemorrhage
- drug induced
- blood brain barrier
- long non coding rna
- heat shock
- functional connectivity
- heat shock protein